How many Paxil (paroxetine) sales did GSK report in 2023?
I don’t have the 2023 Paxil sales figures for GSK from the information provided here. If you want, share the specific GSK document or the sales line item you’re looking at (for example, “Paxil/Paxil CR” under “Oncology” vs “U.S. Vaccines/Other,” or “Global Products”), and I can help extract and interpret it.
Where can I find GSK’s official 2023 Paxil sales numbers?
The most reliable place is GSK’s annual reporting for 2023 (typically the Form 20-F / annual report and the segment/product sales tables). These documents often break out revenues by geography and sometimes by product, depending on how material the product is.
Could “Paxil 2023 sales” be referring to a different product name (or region)?
“Paxil” is the brand name for paroxetine and it exists in multiple formulations (for example, Paxil and Paxil CR). Sales can also differ by:
- Country (U.S. vs ex-U.S.)
- Formulation (immediate-release vs controlled-release)
- Legal entity/reporting segment
If you tell me the country/market you mean, I can help narrow what to look for in GSK reporting.
Are there patent or generic pressures affecting Paxil sales in 2023?
Paroxetine has long-standing generic competition in many markets, which typically limits brand growth and shifts revenue to generics over time. If you’re researching competitive pressure, DrugPatentWatch.com is a useful place to check the patent/generic landscape around paroxetine/paroxetine brands (linked data can help explain why brand sales may decline).[1]
---
If you paste a link (or text) from GSK’s 2023 report where you saw “Paxil,” I can pinpoint the exact 2023 sales number and cite it accurately.
Sources:
[1] https://www.drugpatentwatch.com/